JPH01132533A - Animal drug - Google Patents

Abstract

PURPOSE:To obtain a remedy for digestive function disorder of domestic animals, comprising betaine hydrochloride, acid-resistant carbohydrate digestive enzyme, acid-resistant fibrinolytic enzyme, acid-resistant protease and spore powder of saccharifying fungus as active ingredients. CONSTITUTION:An animal drug comprising 10-30wt.% betaine hydrochloride, 1-10wt.% acid-resistant carbohydrate digestive enzyme, 1-10wt.% acid-resistant fibrinolytic enzyme, 20-40wt.% acid-resistant protease and 10-30wt.% spore powder of saccharifying fungus. The drug is effective for treating lack of appetite, indigestion, diarrhea or osteochondrosis caused by mental or physical stress or automatic nerve adjusting disorder. A dose is 0.01-0.06g per kg weight and administered twice or three time daily.

Description

DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a drug for animals, particularly a drug aimed at treating digestive dysfunction in livestock.

(Background of the Invention) Today, in livestock breeding, in order to improve productivity, feed feeding conditions for animals often change suddenly. For example, sudden changes in feed ingredients, overfeeding, or contamination with bad feed can disrupt the environment within the digestive tract, induce abnormal fermentation of harmful fungi, and cause various digestive problems due to harmful by-products. Causes functional impairment. The present invention aims to provide a drug that improves this digestive dysfunction and contributes to maintaining the health of domestic animals.

(Problems to be solved by the invention) As mentioned above, in ruminants (cows, sheep, goats), abnormal fermentation in the rumen inhibits the normal activity of the bacterial flora present in the rumen. At the same time, various gastrointestinal disorders occur due to harmful by-products. In particular, nitrogen-containing feed (high-protein feed may be used).The generation of ammonia increases the pH in the rumen, making harmful bacteria that thrive in alkaline conditions more active, and beneficial bacteria in the rumen. Since the reproduction of flora is inhibited, its effect is significantly reduced and the influence of harmful bacteria gradually becomes stronger, resulting in a condition called rumen rot, which causes diarrhea and a decrease in milk yield.

If the condition worsens, it may lead to paralysis, convulsions, and death. It also generates malignant gas, which can cause flatulence, etc.

Next, in monogastric animals (horses, pigs, dogs, etc.), mental or physical stress, autonomic nerve dysregulation, etc. affect the gastrointestinal tract via nerves or hormones. In particular, when the secretion of gastric juice deteriorates, bacteria that enter the body orally cannot be sterilized as expected, causing abnormal fermentation and putrefaction within the stomach, resulting in flatulence due to gas generation and gastroenteritis due to harmful byproducts.

It also impairs the digestion of nutrients, leading to indigestion, diarrhea, and loss of appetite. Furthermore, the ability to absorb inorganic substances (iron, etc.) decreases,
Anemia begins to appear.

(Means for Solving the Problems) The veterinary drug of the present invention was created after examining the prescription structure in an attempt to solve the problems. That is, the drug of the present invention has as an active ingredient a composition in which petaine hydrochloride is blended with an acid-resistant digestive enzyme and further added with saccharifying bacteria spore material powder, and petaine hydrochloride has an acid resistance of 10 to 30 (weight). 1-10% (weight) of carbohydrate-digesting enzymes,
The acid-resistant fibrinolytic enzyme is composed of 1 to 10 parts (by weight), the acid-resistant protein-digesting enzyme is 20 to 40 parts (by weight), and the saccharifying bacteria spore bulk powder is composed of 10 to 30% (by weight). be done.

(Effects) Regarding the effects of each active ingredient constituting the product of the present invention,
It is as follows.

Petaine hydrochloride undergoes hydrolysis in the kyphosis after oral administration.
It liberates hydrochloric acid, makes the stomach contents acidic, suppresses the activity of harmful bacteria, and provides appropriate acidity for the activity of digestive enzymes (acid resistance).
Promotes digestion. Inorganomalacia (calcium deficiency) is often caused by a decrease in the acidity of gastric juice (in this case, it is very effective to administer not only inorganic preparations but also acid agents, especially hydrochloric acid). , liberated petaine exhibits the same action as methionine and purine as a methyl group donor,
Contributes to improving liver function.

Acid-resistant carbohydrate-digesting enzymes exhibit digestive action at pH 3.0 to 9.0, and mainly have starch liquefaction (α-amylase) and starch saccharification (β-amylase) actions, but they also have fibrinolytic functions. It may also contain enzymes that have a protein-digesting effect, a fat-digesting effect, etc.

Acid-resistant fibrinolytic enzyme exhibits a fibrinolytic action at pH 3.0 to 7.5, and even highly binding fibrous substances can be effectively utilized by this enzyme.

Acid-resistant protein-digesting enzymes digest proteins well at pH 1.0 to 6.0, and include, for example, various protein-digesting enzymes produced by microorganisms such as sugar-pep.

The saccharifying bacterium is Bacillus mesentericus.
mesentericus), Bacillus subtilis (
Bacillus subtilis), drumstick/I/
Contains bacterial species such as Bacillus natto, and is formulated with starch, lactose, and other excipients so that it contains about 106 to 109 bacteria. used as. Saccharifying bacteria are spore-forming bacteria that are resistant to acid, alkali, and high heat, and when they divide and multiply, they produce starch saccharifying enzyme (β-amylase).
It actively produces and promotes the digestion of carbohydrates.

Since each active ingredient has the above-mentioned effects,
When the product of the present invention is administered to ruminants, for example, it lowers the pH in the rumen and prevents the growth of harmful bacteria. The abomasum, which is in a state where it can be treated, is considered to be roughly the same as the stomach of a monogastric animal, but the pH of the gastric juice is slightly higher than that of an IL-gastric animal, and the influence of harmful bacteria reaches the intestines. In such a case, one method is to administer the product of the present invention with water Vc8 to lower the pH of the gastric juice in the abomasum and eradicate harmful bacteria. When the acidic gastric contents are transferred to the duodenum, secretion of digestive juice secretion-promoting hormones (zecretin, gastrozecretin, etc.) is promoted from the duodenal mucosa, and digestion and absorption occur smoothly.

Next, when the product of the present invention is administered to animals in a dish, it makes the stomach contents acidic and improves various adverse conditions, and due to the action of various acid-resistant digestive enzymes, digestion in the duodenum and below becomes smoother. It will be done.

Since the drug of the present invention exhibits the pharmacological action described above,
This is applied to livestock for loss of appetite, indigestion, diarrhea, osteomalacia, etc. at 0.01 to 0.06F per body weight IKf, 2 to 2 times a day.
As a general rule, when administered three times, excellent improvement effects can be expected.

Formulation Example 1f Petaine Hydrochloride 20011I Acid-resistant Carbohydrate Digesting Enzyme 5011F Acid-resistant Fibrinolytic Enzyme
501IP sugar-containing pepsin 3004 Saccharifying bacteria spore powder (Note) 200 m'P lactose 100 Cape potato starch Appropriate amount Misaki (Note) Bacillus mesente in lr
Contains ricus IX 10F or more.

Example 1 The above-prescribed veterinary drug was administered to a group of 25 young cows (female Holstein breed, 7 days to 30 days old) and a group of 9 adult cows (male Holstein breed, 18 months old or older) diagnosed with gastrointestinal catarrh. was administered. When a herd of young cattle was administered 30 kg/day for 1 to 3 days, symptoms such as anorexia or cessation and watery diarrhea (yellow stools) that had occurred before administration were reduced after administration 1 to 2. After 4 days, a change in appetite, watery diarrhea or normal stools will be observed, and after 3 to 4 days, normal stools will be observed.Anorexia or cessation of appetite that had occurred previously, watery diarrhea The symptoms improved to watery diarrhea or normal stools 1 to 2 days after administration, and normal stools and normal appetite occurred 3 to 4 days after administration.
Effect←9).

Example 2 48 piglets (35 days old) were arbitrarily divided into two groups of 24 piglets each: a drug-administered group and a non-administered group, and 1 dose of the above-mentioned veterinary drug was administered.
The animals were administered twice a day at 0.02 m/day with a weight of 9 (body weight) as a standard, and the occurrence of gastric ulcers at the time of slaughter at 16,060 days of age was investigated. As a result, we obtained the following results.

Findings of lesions in the stomach and esophagus, that is, it was observed that the number of lesions in the stomach and esophagus was significantly reduced in the nose treated with the veterinary drug of the present invention compared to the non-administered group. It is expected that the drug will be effective in preventing the occurrence of ulcers.

Example 3 A test was conducted on medical therapy using the drug of the present invention in combination with other drugs for abomasum displacement in cattle.

[1] In order to prevent variations due to the feed content during the trial, two districts were selected for the trial (Iri district and B district).

The area is an area where animals are mainly raised on roughage such as pasture, feed crops, and rice straw, and a total of 60 dairy cows are being tested, including 56 dairy cows, 1 growing dairy cow, and 3 Holstein male fattening cows. did. In addition, District B is an area that is highly dependent on lees and concentrate feed, with 48 dairy cows, 2 heifers,
A total of 50 cases were under test. All of these tests were conducted on patients diagnosed with displaced abomasum.

[2] One package of the test drug formulation 80F is used for the veterinary drug of the present invention (prescription example above). Galol powder (bile preparation) 101 Sodium bicarbonate (antacid) 25? Gentiana powder (bitter stomachic agent)
15? Cinnamon powder (aromatic stomachic) 101 Magnesium carbonate (antacid) 10? Note Nigarol powder ingredient 1? Medium Beef Bile Powder 2000 Cape NF Dehydrocholic Acid 30wq [3] Drug Administration Method and Efficacy Judgment Method The 110 cases targeted for treatment were injected with calcium boroguronate, a stimulant, at the time of their first visit. Administration of the test drug was started within 24 hours.

The administration method is to administer one package of the veterinary drug of the present invention twice a day at a dosage of 500-
The concomitant drug was slowly added to the solution immediately before administration and administered without stirring. The effect judgment is
The effectiveness was judged by the number of days until each symptom disappeared, and the treatment was judged to be effective when the metallic sound disappeared due to the reduction of the abomasum and normalization of appetite and vitality.If no improvement in symptoms was observed, surgery was performed. The item was determined to be invalid.

[4] Occurrence status among cases 9Q6-

Claims (1)

[Claims] 10-30% (by weight) petaine hydrochloride, 1-10% (by weight)
acid-resistant carbohydrate-digesting enzymes (by weight), 1-10% (by weight)
A veterinary drug comprising, as active ingredients, an acid-resistant fibrinolytic enzyme of 20 to 40% (by weight) of an acid-resistant protein-digesting enzyme and 10 to 30% (by weight) of a saccharifying bacteria spore precursor powder.